83 related articles for article (PubMed ID: 30741319)
1. Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2019 Mar; 97(3):435-436. PubMed ID: 30741319
[TBL] [Abstract][Full Text] [Related]
2. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
4. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.
Hoshikawa Y; Kwon HJ; Yoshida M; Horinouchi S; Beppu T
Exp Cell Res; 1994 Sep; 214(1):189-97. PubMed ID: 8082721
[TBL] [Abstract][Full Text] [Related]
6. Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.
Zhang X; Jiang SJ; Shang B; Jiang HJ
Thorac Cancer; 2015 Mar; 6(2):202-8. PubMed ID: 26273359
[TBL] [Abstract][Full Text] [Related]
7. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
[TBL] [Abstract][Full Text] [Related]
8. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
10. Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling.
Zhang Y; Zhang B
J Biochem Mol Toxicol; 2016 Apr; 30(4):163-9. PubMed ID: 26509796
[TBL] [Abstract][Full Text] [Related]
11. Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK-ERK activation.
Potočnjak I; Gobin I; Domitrović R
Phytother Res; 2018 Jun; 32(6):1090-1097. PubMed ID: 29417642
[TBL] [Abstract][Full Text] [Related]
12. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S
Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997
[TBL] [Abstract][Full Text] [Related]
14. Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis.
Hakami NY; Dusting GJ; Peshavariya HM
J Cell Mol Med; 2016 Oct; 20(10):1932-44. PubMed ID: 27297729
[TBL] [Abstract][Full Text] [Related]
15. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
[TBL] [Abstract][Full Text] [Related]
17. Synergistic killing of human leukemia cells by antioxidants and trichostatin A.
Kang J; Chen J; Zhang D; Da W; Ou Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):537-45. PubMed ID: 15248029
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Kim SO; Kim MR
Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells.
Roh MS; Kim CW; Park BS; Kim GC; Jeong JH; Kwon HC; Suh DJ; Cho KH; Yee SB; Yoo YH
Apoptosis; 2004 Sep; 9(5):583-9. PubMed ID: 15314286
[TBL] [Abstract][Full Text] [Related]
20. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Sun P; Zhou X; He Y; Liu H; Wang Y; Chen Y; Li M; He Y; Li G; Li Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):990-996. PubMed ID: 29462617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
